- Home
- APLT vs SMR Comparison
APLT vs SMR Comparison
Compare APLT & SMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- SMR
- Stock Information
- Founded
- APLT 2016
- SMR 2007
- Country
- APLT United States
- SMR United States
- Employees
- APLT N/A
- SMR N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- SMR Electrical Products
- Sector
- APLT Health Care
- SMR Industrials
- Exchange
- APLT Nasdaq
- SMR Nasdaq
- Market Cap
- APLT 128.0M
- SMR N/A
- IPO Year
- APLT 2019
- SMR N/A
- Fundamental
- Price
- APLT $0.96
- SMR $17.93
- Analyst Decision
- APLT Buy
- SMR Buy
- Analyst Count
- APLT 7
- SMR 5
- Target Price
- APLT $6.10
- SMR $11.50
- AVG Volume (30 Days)
- APLT 8.9M
- SMR 8.8M
- Earning Date
- APLT 11-07-2024
- SMR 11-07-2024
- Dividend Yield
- APLT N/A
- SMR N/A
- EPS Growth
- APLT N/A
- SMR N/A
- EPS
- APLT N/A
- SMR N/A
- Revenue
- APLT N/A
- SMR $7,381,000.00
- Revenue This Year
- APLT N/A
- SMR N/A
- Revenue Next Year
- APLT $2,664.24
- SMR $278.07
- P/E Ratio
- APLT N/A
- SMR N/A
- Revenue Growth
- APLT N/A
- SMR N/A
- 52 Week Low
- APLT $0.77
- SMR $1.88
- 52 Week High
- APLT $10.62
- SMR $32.30
- Technical
- Relative Strength Index (RSI)
- APLT 18.39
- SMR 40.00
- Support Level
- APLT $0.78
- SMR $17.36
- Resistance Level
- APLT $0.90
- SMR $22.35
- Average True Range (ATR)
- APLT 0.11
- SMR 2.10
- MACD
- APLT 0.25
- SMR -0.39
- Stochastic Oscillator
- APLT 14.76
- SMR 17.32
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.